Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients

The objective of this study was to evaluate whether genetic polymorphisms of CYP2C19, CYP3A5 and MDR1 significantly impact the interaction between tacrolimus and rabeprazole or lansoprazole. Seventy‐three recipients were randomly assigned after renal transplantation to receive repeated doses of tacrolimus for 28 days with a regimen of either 20 mg of rabeprazole or 30 mg of lansoprazole. Blood concentrations of tacrolimus were measured by microparticle enzyme immunoassay. The mean daily dose and the dose‐adjusted area under the plasma concentration‐time curves from 0 to 12 h (AUC0–12) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng·h/ml/mg/kg, respectively). On the other hand, the mean dose‐adjusted AUC0−12 of tacrolimus coadministered with rabeprazole or lansoprazole were the highest in CYP2C19 PMs having the MDR13435CC+CT genotype, but not significantly.

[1]  T. Habuchi,et al.  Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes , 2006, European Journal of Clinical Pharmacology.

[2]  T. Habuchi,et al.  Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. , 2005, Transplantation proceedings.

[3]  T. Habuchi,et al.  Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  T. Sakaeda,et al.  Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells. , 2004, Biological & pharmaceutical bulletin.

[5]  M. Miura,et al.  Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  M. Kasuga,et al.  CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects , 2001, Pharmaceutical Research.

[7]  P. Beaune,et al.  Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  M. Homma,et al.  Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. , 2002, Transplantation proceedings.

[9]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[11]  J. Azuma,et al.  Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.

[12]  M. Kasuga,et al.  Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.

[13]  M. Homma,et al.  Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. , 2002, Transplantation.

[14]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[15]  M. Fromm,et al.  Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[16]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[17]  J. Martorell.,et al.  Mycophenolic Acid Plasma Concentrations: Influence of Comedication , 2001, Therapeutic drug monitoring.

[18]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  U. Klotz.  Pharmacokinetic Considerations in the Eradication of Helicobacter Pylori , 2000, Clinical pharmacokinetics.

[20]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[21]  T. Suzuki,et al.  A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. , 1999, Biological & pharmaceutical bulletin.

[22]  C. Nakamura,et al.  Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.

[23]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[24]  S. Binkley,et al.  Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.

[25]  U. Christians,et al.  Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[26]  Kaoru Kobayashi,et al.  Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status , 1995, Clinical pharmacology and therapeutics.

[27]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[28]  D. Dunn,et al.  Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. , 1995, Journal of the American College of Surgeons.

[29]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[30]  I. Yamatsu,et al.  Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. , 1991, Biochemical pharmacology.

[31]  H. Satoh,et al.  Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[32]  N. Takeguchi,et al.  The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. , 1990, Biochemical pharmacology.